Chemistry:7-Methylxanthine
 | |
| Clinical data | |
|---|---|
| Other names | 7-MX; 7-Methylxanthin; Heteroxanthin; Heteroxanthine; NSC-7861 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6H6N4O2 |
| Molar mass | 166.140 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
7-Methylxanthine (7-MX), also known as heteroxanthine, is an active metabolite of caffeine (1,3,7-trimethylxanthine) and theobromine (3,7-dimethylxanthine).[1][2] It is a non-selective antagonist of the adenosine receptors.[1][2] The compound may slow the progression of myopia (nearsightedness).[1][2] It is under investigation for this purpose in children with myopia.[1][2]
It is shown that systemic treatment with 7-mx appears to be efficient in retarding axial elongation and myopia progression among myopic children. The treatment is safe and without side effects, and may be continued until 18–20 years of age, when age-related cross-linking of collagen prevents further elongation of the eye.[3] Additionally, further studies show that oral intake of 7-MX was associated with reduced myopia progression and reduced axial elongation in this sample of myopic children from Denmark. Randomised controlled trials are needed to determine whether the association is causal.[4]
References
- ↑ 1.0 1.1 1.2 1.3 "7-Methylxanthine". https://drugs.ncats.io/drug/E9M81NJM6G.
- ↑ 2.0 2.1 2.2 2.3 "Myopia, its prevalence, current therapeutic strategy and recent developments: A Review". Indian Journal of Ophthalmology 70 (8): 2788–2799. August 2022. doi:10.4103/ijo.IJO_2415_21. PMID 35918918.
- ↑ "Systemic 7-methylxanthine in retarding axial eye growth and myopia progression: a 36-month pilot study". Journal of Ocular Biology, Diseases, and Informatics 1 (2–4): 85–93. December 2008. doi:10.1007/s12177-008-9013-3. PMID 20072638.
- ↑ "Oral administration of caffeine metabolite 7-methylxanthine is associated with slowed myopia progression in Danish children". The British Journal of Ophthalmology 107 (10): bjophthalmol–2021–320920. August 2022. doi:10.1136/bjo-2021-320920. PMID 35995571.
 |  |
